To the Editor: Denosumab, a receptor activator of nuclear factor κ-B (RANK) ligand inhibitor, is now considered first-line therapy to prevent skeletal-related events in patients with bone metastases secondary to breast cancer and castration-resistant prostate cancer.1,2
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011; 377: 813-822.
- 2. Stopeck AT, Lipton A, Body J, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomised, double-blind study. J Clin Oncol 2010; 28: 5132-5139.
- 3. Autio KA, Farooki A, Glezerman I, et al. Risk assessment for severe hypocalcemia requiring hospitalisation with denosumab [abstract]. J Clin Oncol 2013; 31 Suppl 6: abstr 115.
- 4. Block GA, Bone HG, Fang L, et al. A single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res 2012; 27: 1471-1479.
- 5. Cooper MS, Gittoes NJ. Diagnosis and management of hypocalcaemia. BMJ 2008; 336: 1298.
Online responses are no longer available. Please refer to our instructions for authors page for more information.
We thank the patient for allowing us to report this case.
No relevant disclosures.